推薦產品
生物源
mouse
品質等級
抗體表格
purified immunoglobulin
抗體產品種類
primary antibodies
無性繁殖
6D7, monoclonal
物種活性
human, mouse, rat
包裝
antibody small pack of 25 μg
技術
ChIP: suitable
western blot: suitable
同型
IgG1κ
NCBI登錄號
UniProt登錄號
運輸包裝
ambient
目標翻譯後修改
unmodified
基因資訊
human ... NRIP1(8204)
一般說明
Nuclear receptor-interacting protein 1 (UniProt: P48552; also known as Nuclear factor RIP140, Receptor-interacting protein 140) is encoded by the NRIP1 gene (Gene ID: 8204) in human. RIP140 is a nuclear protein that is localized to discrete foci and redistributes to larger nuclear domains upon binding to ligand-bound NR3C1. It is expressed in liver in a circadian manner. RIP140 contains 9 Leu-Xaa-Xaa-Leu-Leu (LXXLL) motifs, which have different affinities for nuclear receptors. The C-terminal LTKTNPILYYMLQK motif is required for ligand-dependent interaction with retinoic acid (RA) receptor-alpha (RARA) and retinoid X receptor beta (RXRB) homodimers and heterodimers, for the corepressor activity, and for the formation of an HDAC3 complex with RARA/RXRB. It also contains at least four autonomous repression domains (RD1-4). RD1 functions via a histone deacetylase (HDAC)-independent mechanism, whereas RD2, RD3 and RD4 can function by HDAC-dependent or independent mechanisms, depending on cell type. RIP140 Acetylation regulates its nuclear translocation and co-repressive activity of RIP140 is regulated by its acetylation, which is shown to abolish its interaction with C-terminal-binding protein 1 (CTBP1). Several glucocorticoid responses are shown to be deregulated by RIP140 possibly via an interaction between the glucocorticoid receptor (GR), which prevents binding of true co-activator with GR. (Ref.: Subramaniam N, et al. (1999). J. Biol. Chem. 274(25):18121-7).
特異性
Clone 6D7 detects Nuclear receptor-interacting protein 1 (RIP140) in human, mouse, and rat cells. It targets an epitope with in 178 amino acids from the N-terminal half.
免疫原
GST-tagged recombinant fragment corresponding to 178 amino acids from the N-terminal half of human Nuclear receptor-interacting protein 1 (RIP140).
應用
Anti-RIP140, clone 6D7, Cat. No. MABS1917, is a mouse monocloanl antibody that detects RIP140 and has been tested for use in Chromatin Immunoprecipitation (ChIP) and Western Blotting.
Research Category
Signaling
Signaling
Western Blotting Analysis: A representative lot detected RIP140 in Western Blotting applications (Kiskinis, E., et. al. (2007). EMBO J. 26(23):4831-40; Hallberg, M., et. al. (2008). Mol Cell Biol. 28(22):6785-95).
Chromatin Immunoprecipitation Analysis: A representative lot detected RIP140 in Chromatin Immunoprecitpiation applications (Hallberg, M., et. al. (2008). Mol Cell Biol. 28(22):6785-95).
Chromatin Immunoprecipitation Analysis: A representative lot detected RIP140 in Chromatin Immunoprecitpiation applications (Hallberg, M., et. al. (2008). Mol Cell Biol. 28(22):6785-95).
品質
Evaluated by Western Blotting in MCF7 cell lysate.
Western Blotting Analysis: 1 µg/mL of this antibody detected RIP140 in 10 µg of MCF7 cell lysate.
Western Blotting Analysis: 1 µg/mL of this antibody detected RIP140 in 10 µg of MCF7 cell lysate.
標靶描述
~160 kDa observed; 126.94 kDa calculated. Uncharacterized bands may be observed in some lysate(s).
外觀
Protein G purified
Format: Purified
Purified mouse monoclonal antibody IgG1 in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.
儲存和穩定性
Stable for 1 year at 2-8°C from date of receipt.
其他說明
Concentration: Please refer to lot specific datasheet.
免責聲明
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
未找到適合的產品?
試用我們的產品選擇工具.
儲存類別代碼
12 - Non Combustible Liquids
水污染物質分類(WGK)
WGK 1
分析證明 (COA)
輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。
Experimental gerontology, 143, 111111-111111 (2020-10-18)
To evaluate the safety and feasibility of combining exercise (EX) and resveratrol to treat older adults with physical function limitations. Three-arm, two-site pilot randomized, controlled trial (RCT) for community-dwelling adults (N = 60), 71.8 ± 6.3 years of age with functional limitations. Participants were randomized
我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務